RecruitingPhase 1NCT07193628

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Principal Investigator
Feng Yan, MD & PhD
Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine
Intervention
EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)(biological)
Enrollment
14 target
Eligibility
18-75 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07193628 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials